Company profile
Oxford MediStress - Home
Oxford Medistress Ltd is a UK company with status active founded in 2005 based in London.
Reference milestones and recent Companies House filing stream events.
Next accounts due date
Next confirmation statement due date
AA | Transaction MzUxMjk1OTYzMGFkaXF6a2N4
Published 27 Mar 2026 11:28
Last accounts made up date
Last confirmation statement made up date
Company registered at Companies House
1 Jun 2023 to 31 Jan 2024
The unique solution combines the use of the only technology to objectively assess the worker's ability to cope with job demands, with an accessible digital referral platform for SME managers and the self employed, and connects these with occupational health service providers. The technology used is the Leucocyte CopingCapacity(TM) (LCC(TM)) test, a minima...
1 Jun 2020 to 28 Feb 2021
Oxford MediStress is developing the advanced Leukocyte ImmunoTest (LIT)(tm) as a rapid (10-minute) fingerprick in vitro blood test to assess how well an individual's immune system is functioning. In previous studies involving patients with a variety of cancers, we have demonstrated the clinical potential of the technique. Results from the recent FORECAST ...
1 Apr 2019 to 31 Mar 2020
"Drug companies are continuing to develop new and improved drugs and medications in the fight against cancer, and more cancer patients are benefiting from these so-called ""chemotherapy"" drugs. However, a key challenge is the risk of unwanted drug side effects which are called adverse drug responses (ADRs). A common ADR that is also quite severe affects ...
1 Feb 2019 to 31 Jan 2020
"Prostate cancer is the most common cancer in European males, with over 340,000 new cases and 71,000 deaths each year in the EU. Indeed, experts predict up to 1 in 8 men in the EU will be diagnosed with prostate cancer during their lifetime. Significant progress has been made in recent years in detecting the onset of prostate cancer. In particular, prosta...
1 Jun 2015 to 30 Sep 2015
Affecting one in three people over the course of their lifetimes, cancer represents a significant burden to healthcare systems around the world, costing the UK economy £11 billion annually. Oxford MediStress, an Oxford University spinout company, has recently developed a new fingerprick blood test that allows the quantitative assessment of a key component...
1 Feb 2015 to 31 Jul 2015
Affecting one in three people over the course of their lifetimes, cancer represents a significant burden to healthcare systems around the world, costing the UK economy £11 billion annually. Oxford MediStress, an Oxford University spinout company, has recently developed a new fingerprick blood test that allows the quantitative assessment of a key component...
